Own experience in treating patients with progression of anaplastic astrocytomas of the brain. Factors influencing survival
- 23 April 2024
- journal article
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (4)
Abstract
Objective. To determine significant factors influencing treatment results, as well as to select the optimal approach to treatment tactics for patients with progression of anaplastic astrocytomas of the brain. Material and methods. The study included 60 patients who were treated in the period from 2006 to 2021 in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. The average age of the patients was 42.9±12.2 years. The male to female ratio is 1.5:1. The main treatment methods were a combination of surgical treatment with chemotherapy with temozolomide (10 people) and radiation therapy (8 people); monochemotherapy with temozolomide (12 people); 23 people received radiation therapy and 7 people received chemoradiation therapy. Results. The median overall survival (OS) of patients was 48 months, 1-year OS rates were 94.7%; 2-year OS — 78.6%; 3-year OS — 63.7%, 5-year OS — 37.4%. Median progression-free survival (PFS) after treatment of relapse was 24 months. The median OS in patients operated on after the development of relapse was 58 months, while without surgery it was 48 months, the difference was not statistically significant. At the same time, the best PFS rates were observed with reoperation followed by radiation therapy — 35 months, as well as with radiation without surgery — 24 months. (p=0.897). Among radiotherapy techniques, the best OS and PFS rates were observed in patients who underwent courses of combined photon-neutron therapy — 84 months. and 47 months respectively. Conclusion. Thus, factors positively influencing the rates of OS and VBP include repeated surgical treatment and combined neutron-photon therapy. Repeated course of combined photon-neutron therapy may be a necessary component of treatment of this category of patients.Keywords
This publication has 13 references indexed in Scilit:
- Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade AstrocytomasClinical Cancer Research, 2021
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsNeuro-Oncology, 2020
- Repeat Resection and Intraoperative Radiotherapy for Malignant Gliomas of the Brain: A History and Review of Current TechniquesWorld Neurosurgery, 2019
- A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital BiomarkersCurrent Treatment Options in Oncology, 2019
- Patterns of re-irradiation for recurrent gliomas and validation of a prognostic scoreRadiotherapy and Oncology, 2019
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trialThe Lancet Oncology, 2018
- A Retrospective Review of Re-irradiating Patients' Recurrent High-grade GliomasClinical Oncology, 2018
- Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trialJournal of Neuro-Oncology, 2017
- Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Neuro-Oncology, 2016
- Temozolomide for recurrent high-grade gliomaSeminars in Oncology, 2001